Guggenheim 3rd Annual Healthcare Innovation Conference - PHARVARIS NV

Financial Performance:

• No specific financial figures (revenue, earnings, cash flow, debt) provided in the transcript; the company is pre-revenue with a pipeline focused on clinical development.
• Financial strategy emphasizes a holistic portfolio approach (on-demand + prophylaxis) to maximize value rather than pricing a single asset in isolation.
• Management indicates strong confidence in the "compelling" pricing corridors for both on-demand ($17,800/dose reference) and prophylaxis segments.
• Potential for non-dilutive funding via international (XUS) partnerships is under consideration but not yet committed.

Guidance and Future Outlook:

• NDA Submission (Prophylaxis): Targeting submission for prophylactic treatment of Hereditary Angioedema (HAE) in the first half of 2027, contingent on completing the Phase 4 long-term safety database.
• Topline Data Release: Anticipating top-line data from the CREATE study (prevention of acquired angioedema attacks) in Q1 2027.
• Approval Timeline: Aiming for U.S. commercial launch in April 2027.
• Global Strategy: U.S. is the immediate priority; international expansion (Japan, Europe) and XUS partnership models are in early discussion phases.

Business Segments and Product Lines:

• Product: Ducritaban (also referred to as Ducretibine/Decrietoband) is the lead compound with two formulations: an on-demand treatment and a prophylactic treatment.
• Clinical Development:
  • On-demand: Pivotal Phase 3 data read out in December; mechanism is a B2 receptor antagonist.
  • Prophylaxis: Pivotal Phase 3 data read out in September; demonstrates "injectable-like efficacy."
• Indication Strategy: Aiming for a broad label covering both Hereditary Angioedema (HAE) and Bradykinin-mediated Angioedema (including Acquired Angioedema) to potentially secure priority review.
• Commercial Readiness: Approximately 90% of the U.S. commercial team is hired, including 30–40 sales reps targeting ~2,500 allergists and physicians.

Market and Competitive Landscape:

• Competitive Dynamics: Views the market as crowded but believes oral therapies will dominate the on-demand segment due to convenience and discretion compared to injectables (e.g., C1 esterase inhibitors, Icatibant).
• Differentiation:
  • Vs. Orladeo (Berotralstat): Higher single-dose response rate (83% vs. ~47%); faster onset.
  • Vs. Ecteral (Ecallantide): Superior single-dose resolution (83% vs. 38-39% for Ecteral); addresses the need to take a second dose.
  • Vs. Icatibant: Oral administration avoids injection site issues and stinging associated with injectables.
• Market Demand: High demand for oral therapies exists among patients currently on suboptimal oral therapies or those tired of injectables.

Risks and Challenges:

• Safety Concerns: Two patients in Phase 3 experienced Grade 3 liver enzyme elevations (attributed to pre-existing fatty liver disease or prior anabolic treatment); however, overall safety profile regarding cardiovascular and GI events is reported as clean.
• Regulatory Uncertainty: Final label negotiations with the FDA regarding primary endpoints (rapid onset, complete resolution, single-dose durability) are ongoing; no formal bonding agreement exists for combining HAE and Acquired Angioedema datasets.
• Disease Context: HAE patients often have fragile livers due to C1 deficiency and long-term androgen use, making liver enzyme elevations a known background risk in this population.
• Market Saturation: Potential challenges in switching patients from established competitors like Orladeo or Tuxero (exanide) due to patient loyalty or specific treatment preferences.

Management Commentary and Tone:

• Tone: Highly confident, optimistic, and professional; management emphasizes the scientific translation from novel science to patient benefit.
• Strategic Focus: Emphasis on solving the "trilemma" of efficacy, tolerability, and convenience by offering oral efficacy comparable to injectables.
• Team Strength: Pride expressed in the deep roots of both R&D and commercial teams in the rare disease field and strong relationships with patient advocacy groups.

Analyst Questions and Answers:

• Q: NDA Strategy & CREATE Data: Management confirmed that while the safety database is the technical limit, the CREATE data will align with the NDA submission to support a broader "bradykinin-mediated" label.
• Q: Safety Profile & FDA: Clarified that liver enzyme elevations are comparable to other prophylactic trials and not unexpected given the patient population's comorbidities; cardiovascular safety was a specific focus and was clean.
• Q: Pricing & Competition: Management declined to specify exact pricing but noted the goal is rapid patient access via creative contracting and sampling; pricing will leverage the dual portfolio (on-demand + prophylaxis).
• Q: International Launch: Confirmed no final commitment on XUS strategy (partner vs. self-run), with MAA currently under review; Japan and Europe are prioritized next.
• Q: Label Differentiation: Highlighted three key label differentiators: rapid onset (1.28 hours), complete symptom resolution (<12 hours), and single-dose durability (83% success).

Other Key Points:

• Mechanism of Action: Ducritaban acts as a B2 receptor antagonist, sharing the same MOA as the current market-leading injectable, Icatibant, but in oral form.
• Baseline Attack Rates: Phase 3 baseline attack rates (approx. 3.6/month) are consistent with other pivotal trials in the space (3.5–3.6).
• Drug Switching: A significant portion of international patients (20-30% in AP/Latin America) still utilize Danazol, compared to <5% in the U.S., offering a potential switch population for oral alternatives.